Comparison of the activities of four antifungal agents in an in vitro model of dermatophyte nail infection

Indian Journal of Dermatology

Volumn 53, Issue 3, 2008, Pages 125-128

  Nowrozi, Hossein ^a,e   Nazeri, Golrokh ^b   Adimi, Parvaneh ^c   Bashashati, Mohsen ^d   Emami, Masood ^c  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antifungal; Culture media; Nail; Onychomycosis

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; KETOCONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DERMATOPHYTE; EPIDERMOPHYTON FLOCCOSUM; FUNGUS CULTURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO CULTURE; MICROSPORUM CANIS; MINIMUM INHIBITORY CONCENTRATION; NAIL INFECTION;

EID: 53849088204     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.43216     Document Type: Article

References (17)

1. Blumberg M, Kantor GR. (Internet): Onychomycosis. Available from: http://www.emedicine.com/derm/topic300.htm.
2. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003;149:1-4.
3. Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004;42:159-63.
4. Len J, Chem W, Buchta R, et al. A multi-model approach for the evaluation of topical antifungal agents and formulation for the treatment of onychomycosis.http://www.medpharm.co.uk/news/documents/ 2007FocusAntifungal_posterl.pdf
5. Yazdanparast SA, Barton RC. Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol 2006;55:1577-81.
6. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001;39:385-8.
7. Santos DA, Hamdan JS. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 2006;44:357-62.
8. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39:314-9.
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1997.
10. Osborne CS, Leitner L, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004;42:159-63.
11. Evans EG. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol 2003;149:11-3.
12. Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001;145:3-8.
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. Wayne, PA: NCCLS; 2000.
14. Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003;41:4817-9.
15. Rashid A, Scott EM, Richardson MD. Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes. J Am Acad Dermatol 1995;33:718-23.
16. Richardson MD. Effect of Lamisil and azole antifungals in experimental nail infection. Dermatology 1997;194:27-31.
17. Gupta AK, Ahmad I, Summerbell RC. Comparative efficacies of commonly used disinfectants and antifungal pharmaceutical spray preparations against dermatophytic fungi. Med Mycol 2001;39:321-8.